The purpose of this docking was to investigate whether the primary bioactive constituents of the compound played a role in hypoglycemia through the compound's key targets, which were CDK2, E2F1, CDKN1A, CDK1, and CCND1 and CCNB1. This evidence concerns the gene CDK2 and Hypoglycemia.